Search
Now showing items 31-40 of 169
PET imaging to monitor NET-1 and GD2 expression in neuroblastoma
(Institute of Cancer Research (University Of London), 2021-01-31)
Within neuroblastoma (NB), approximately 50% of patients are considered high-risk, presenting widespread distant metastasis and, frequently, MYCN amplification. NB is further characterised by the selective presence of the ...
Investigating the mehcanisms of drug resistance in gastro-intestinal cancers
(Institute of Cancer Research (University Of London), 2020-03-31)
Despite many effective therapies for gastro-intestinal (GI) cancers, both primary and acquired mechanisms of resistance commonly occur. The subclonal complexity of intra-tumoural heterogeneity in these cancers further ...
Functional characterisation of EGFR mutations in cancer
(Institute of Cancer Research (University Of London), 2021-08-31)
Large-scale pan-cancer sequencing of tumour samples has identified a plethora of epidermal growth factor (EGFR) mutations along the full length of the gene. However, clinical studies have demonstrated that distinct mutations ...
Applications of intertumoural, intratumoural and intermolecular heterogeneity for personalised medicine in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-03-31)
Colorectal cancer (CRC) is a heterogeneous disease, both at the molecular level and in the context of patients' responses to treatment. Few biomarkers are currently in place that can help to stratify patients in the clinical ...
Modulation of the tumour immune microenvironment by cancer-associated fibroblasts
(Institute of Cancer Research (University Of London), 2019-11-30)
The breast tumour microenvironment (TME) consists of a variety of non-cancerous cell types that can promote or inhibit cancer progression. Cancer-associated fibroblasts (CAFs) represent a major component of the breast TME ...
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Targeting RIPK1 ubiquitylation to promote anti-tumour immunity
(Institute of Cancer Research (University Of London), 2019-11-30)
Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ...
Magnetic resonance imaging (MRI) guided radiotherapy for prostate cancer
(Institute of Cancer Research (University Of London), 2020-11-30)
Radiotherapy to the prostate involves increasingly sophisticated delivery techniques and changing fractionation schedules. Magnetic resonance imaging (MRI) guided radiotherapy allows daily adaptive replanning and can improve ...
Defining the mechanisms of multi-target tyrosine kinase inhibitor resistance in soft tissue sarcoma
Soft tissue sarcomas (STS) are a rare, heterogeneous, and challenging group of cancers to treat effectively. The approval of pazopanib, as well as promising clinical trial data for a number of other multi-target tyrosine ...
Circulating cell-free DNA methylation analysis of metastatic prostate cancer
(Institute of Cancer Research (University Of London), 2020-03-31)
Introduction; Materials and methods; Deciphering global plasma DNA methylation variance in metastatic prostate cancer; Implementation of a methylation signature for tracking and detection of prostate cancer in plasma; ...